
Quarterly report 2024-Q3
added 11-07-2024
Avinger Revenue 2011-2026 | AVGR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Avinger
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.65 M | 8.27 M | 10.1 M | 8.76 M | 9.13 M | 7.92 M | 9.93 M | 19.2 M | 10.7 M | 11.2 M | 13 M | 8.56 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.2 M | 7.65 M | 10.4 M |
Quarterly Revenue Avinger
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.65 M | 1.85 M | 1.86 M | - | 1.82 M | 2.04 M | 1.89 M | - | 2.25 M | 2.13 M | 1.89 M | - | 2.37 M | 2.8 M | 2.56 M | - | 2.3 M | 1.47 M | 2.26 M | - | 2.41 M | 2.32 M | 1.84 M | - | 2.02 M | 2.06 M | 1.81 M | - | 2.07 M | 2.46 M | 3.49 M | 4.68 M | 5.32 M | 4.68 M | 4.54 M | 2.86 M | 2.72 M | 3.05 M | 2.09 M | 3.07 M | 2.63 M | 3.39 M | 2.12 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.32 M | 1.47 M | 2.58 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 13.26 | 1.14 % | $ 1.79 B | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 10.67 | 2.79 % | $ 382 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Electromed
ELMD
|
64 M | $ 25.74 | 0.12 % | $ 218 M | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.09 | 2.21 % | $ 1.27 M | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.36 | 1.05 % | $ 126 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 57.19 | 1.87 % | $ 1.68 B | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 60.47 | 0.62 % | $ 3.3 B | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 11.24 | 0.54 % | $ 318 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.61 | 0.7 % | $ 38 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.07 | 3.88 % | $ 18.1 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.08 | 0.2 % | $ 5.77 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.41 | 2.32 % | $ 362 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.89 | 1.98 % | $ 1.04 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 307.2 | -2.52 % | $ 117 B | ||
|
TransMedics Group
TMDX
|
605 M | $ 101.25 | 0.46 % | $ 3.44 B | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Tandem Diabetes Care
TNDM
|
290 M | $ 19.98 | 2.3 % | $ 1.36 B | ||
|
Globus Medical
GMED
|
2.94 B | $ 90.77 | 0.65 % | $ 12.3 B | ||
|
NanoVibronix
NAOV
|
2.55 M | - | - | $ 1.08 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 37.22 | 1.53 % | $ 1.16 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 88.24 | -0.31 % | $ 3.07 B | ||
|
Vivos Therapeutics
VVOS
|
17.4 M | $ 0.84 | 4.35 % | $ 8.63 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 84.0 | 0.6 % | $ 49.1 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.21 | -0.38 % | $ 62.3 M | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.33 | 3.52 % | $ 54.1 M | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.57 | 6.25 % | $ 528 M |